The Diversified Value of Pharmaceuticals -A Study from the Public's Perspective and in Light of Changes in the Healthcare Environment
Yosuke Nakano (Senior Researcher, Pharmaceutical and Industrial Policy Research Institute)
Mariko Hirozane (Researcher, Graduate School of Pharmaceutical Sciences, The University of Tokyo)
Naka Igarashi (Associate Professor, Health and Social Medicine Unit, Yokohama City University School of Medicine, Visiting Associate Professor, Pharmaceutical Policy Studies, Graduate School of Pharmaceutical Sciences, The University of Tokyo)
(No. 79: Published in March 2022)
The authors have paid particular attention to social values among the various values of pharmaceuticals, and have investigated the current status of outcome indicators and measurement thereof, as well as the current status of their evaluation overseas (mainly in the United Kingdom and other countries), and reported their findings in Research Paper Series No. 76 (published in March 2021) and elsewhere.
On the other hand, we believe that changes in the healthcare environment due to the COVID-19 pandemic after 2020, the launch of innovative drugs, and the emergence of digital therapeutics and other new technologies will, to a greater or lesser extent, have some impact on the consideration of the various values of drugs.
Based on these changes in the healthcare environment and the latest trends related to value evaluation, this paper reports the results of a questionnaire survey on the various values of pharmaceuticals that the public considers important, as well as new research and discussion related to the various values of pharmaceuticals, supplementing what was not covered in Research Paper Series No. 76. The paper also reports new research and discussion related to the value of pharmaceuticals.